Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib

Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imat...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsumata, Ryo, Monobe, Yasumasa, Katata, Yosuke, Fujiwara, Hideyo, Urano, Takashi, Akagi, Akihisa, Tsujimoto, Kotone, Konishi, Takako, Manabe, Noriaki, Kamada, Tomoari, Kawamoto, Hirofumi, Yamatsuji, Tomoki, Naomoto, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938401/
https://www.ncbi.nlm.nih.gov/pubmed/36820072
http://dx.doi.org/10.1159/000529002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938401/
https://www.ncbi.nlm.nih.gov/pubmed/36820072
http://dx.doi.org/10.1159/000529002

Ejemplares similares